Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the affinity for D-2L, D-4.2, and 5-HT2A receptors
[en] In continuation of our work on N-(piperidin-4-yl)-naphthamides, the effect of substituted benzyl groups on D-2L, D-4.2, and 5-HT2A receptor affinity was evaluated. In the 1-naphthamide series most compounds were highly selective for D-4.2 over D-2L, and 5-HT2A receptors. Halogen and methyl substitution in position 3 or 4 of the benzyl group increased D-4.2 affinity. In the 2-naphthamide series a similar high D-4.2 over D-2L selectivity was retained while 5-HT2A affinity was increased. 3-Methoxy, 3-methyl, and 4-methyl substituents were favorable for D-4.2 affinity while halogens reduced affinity. 2-Naphthamides with a 3-bromo- or a 3-methyl group were mixed D-4.2/5-HT2A ligands similar to their unsubstituted parent compound. All compounds from both series with significant affinity for D-4.2 and 5-HT2A receptors were antagonists. (c) 2007 Elsevier Ltd. All rights reserved.
Liégeois, Jean-François ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Language :
English
Title :
Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the affinity for D-2L, D-4.2, and 5-HT2A receptors
Publication date :
15 March 2007
Journal title :
Bioorganic and Medicinal Chemistry Letters
ISSN :
0960-894X
eISSN :
1464-3405
Publisher :
Pergamon-Elsevier Science Ltd, Oxford, United Kingdom
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Wong A.H.C., and Van Tol H.H.M. Neurosci. Biobehav. Rev. 27 (2003) 269
In: Lidow M.S. (Ed). Neurotransmitter Receptors in Actions of Antipsychotic Medications; Pharmacology and Toxicology Series (2000), CRC Press
Raviña E., and Masaguer C.F. Curr. Med. Chem. CNS Agents 1 (2001) 43
Raggi, M. A. (guest editor) Pharmacological treatment of schizophrenia: Recent antipsychotic drugs and new therapeutic strategies. Curr. Med. Chem. 2004, 11, 267.
Roth B.L., Sheffler D.L., and Kroeze W.K. Nat. Rev. Drug Discov. 3 (2004) 353
Carato, P.; Graulich, A.; Jensen, N.; Roth, B. L.; Liégeois, J.-F. Bioorg. Med. Chem. Lett., (2007), in press, doi:10.1016/j.bmcl.2006.12.096.
Petcher T.J., and Weber H.-P. J. Chem. Soc. Perkin Trans. II (1976) 1415
Liégeois J.-F., Eyrolles L., Ellenbroek B.A., Lejeune C., Carato P., Bruhwyler J., Géczy J., Damas J., and Delarge J. J. Med. Chem. 45 (2002) 5136
Cheng Y.-C., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
Högberg T. Drugs future 16 (1991) 333
Arora J., Bordeleau M., Dube L., Jarvie K., Mazzocco L., Peragine J., Tehim A., and Egle I. Biorg. Med. Chem. Lett. 15 (2005) 5253
Kapur S., and Seeman P. J. Psychiatry Neurosci. 25 (2000) 161
Kapur S., and Seeman P. Am. J. Psychiatry 158 (2001) 360
Nyberg S., Eriksson B., Oxenstierna G., Halldin C., and Farde L. Am. J. Psychiatry 156 (1999) 869
Kramer M.S., Last B., Getson A., and Reines S.A. Arch. Gen. Psychiatry 54 (1997) 567
Gazi L., Bobirnac I., Danzeisen M., Schupbach E., Bruinvels A.T., Geisse S., Sommer B., Hoyer D., Tricklebank M., and Schoeffter P. Br. J. Pharmacol. 124 (1998) 889
Gazi L., Bobirnac I., Danzeisen M., Schupbach E., Langenegger D., Sommer B., Hoyer D., Tricklebank M., and Schoeffter P. Br. J. Pharmacol. 128 (1999) 613
Kotecha S.A., Oak J.N., Jackson M.F., Perez Y., Orser B.A., Van Tol H.H.M., and MacDonald J.F. Neuron 35 (2002) 1111
Rubinstein M., Cepeda C., Hurst R.S., Flores-Hernandez J., Ariano M.A., Falzone T.L., Kozell L.B., Meshul C.K., Bunzow J.R., Low M.J., Levine M.S., and Grandy D.K. J. Neurosci. 21 (2001) 3756
Truffinet P., Tamminga C.A., Fabre L.F., Meltzer H.Y., Riviere M.E., and Papillon-Downey C. Am. J. Psychiatry 156 (1999) 419
Tarazi F.I., Zhang K., and Baldessarini R.J. J. Pharmacol. Exp. Ther. 297 (2001) 711
Tarazi F.I., Zhang K., and Baldessarini R.J. Psychopharmacology 161 (2002) 263
Moran-Gates T., Massari C., Graulich A., Liégeois J.-F., and Tarazi F.I. J. Neurosci. Res. 84 (2006) 675
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.